Medicenna Therapeutics presents updated clinical data on MDNA11

Medicenna Therapeutics (MDNAF) presented updated clinical data from the ongoing Phase 1/2 ABILITY-1 study evaluating MDNA11 in patients with advanced solid tumors at the European Society of Medical Oncology, ESMO, Immuno-Oncology Congress 2025. MDNA11, a long-acting ‘beta-enhanced not-alpha’ interleukin-2 super-agonist, is being evaluated as a monotherapy or in combination with Merck’s (MRK) anti-PD-1 therapy, KEYTRUDA. Key highlights: MDNA11 demonstrates durable anti-tumor activity in phase-2 eligible expansion cohorts, enriched for immune checkpoint resistant melanoma, MSS endometrial cancer, MSI-H and TMB-H cancers, in each case exceeding objective response rate benchmarks in these difficult to treat populations; In the monotherapy expansion cohorts, irrespective of tumor type, patients treated with MDNA11, as the next treatment following progression on immune checkpoint inhibitors, had an ORR of 42% and a disease control rate of 83% underscoring potential of MDNA11 in earlier lines of treatment; Monotherapy expansion cohorts demonstrate ORRs of 38% in melanoma and 22% in MSI-H corresponding to DCR of 75% and 78%, respectively; MDNA11 in combination with KEYTRUDA shows ORR and DCR of 50% and 75%, respectively, for MSS endometrial cancer while MSS TMB-H tumors demonstrated ORR and DCR of 25% and 88%, respectively; Monotherapy and combination treatment achieve durable responses in multiple advanced metastatic tumors, including pancreatic, breast, colorectal, endometrial, bladder, anal cancer and melanoma; Tumor control was associated with significantly prolonged median overall survival in both monotherapy and combination cohorts